Empiric antifungal therapy in patients with febrile neutropenia

Pharmacotherapy

Volumn 31, Issue 4, 2011, Pages 369-385

  Ferrara, Jenna J ^a   MacDougall, Conan ^b   Gallagher, Jason C ^c  

^a St Margaret Memorial Hospital   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c TEMPLE UNIVERSITY   (United States)

Author keywords

Antifungal; Empiric antifungal therapy; Febrile neutropenia; Neutropenia; Neutropenic fever

Indexed keywords

ALEMTUZUMAB; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B DERIVATIVE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CASPOFUNGIN; DEFEROXAMINE; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; PLACEBO; POSACONAZOLE; PYRROLE DERIVATIVE; VORICONAZOLE;

ASPERGILLOSIS; CANDIDIASIS; CHILL; COMORBIDITY; DISEASE PREDISPOSITION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERANCE; DRUG USE; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FLUSHING; FUNGAL COLONIZATION; FUSARIOSIS; HUMAN; HYPERBILIRUBINEMIA; HYPOKALEMIA; INFECTION RISK; INJECTION SITE REACTION; IRON OVERLOAD; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; MYCOSIS; NEPHROTOXICITY; NEUTROPHIL COUNT; NONHUMAN; REVIEW; SIDE EFFECT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTIFUNGAL AGENTS; FEVER; HUMANS; MYCOSES; NEUTROPENIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TREATMENT OUTCOME;

EID: 79953692393     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.31.4.369     Document Type: Review

References (58)

1. Wingard JR. Empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis 2004;39(suppl 1):S38-43.
2. Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006;43:25-31. (Pubitemid 43939072)
3. Cornely OA, Bohme A, Buchheidt D, et al. Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies: recommendations of the infectious diseases working party of the German Society for Haematology and Oncology. Haematologica 2009;94:113-22.
4. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-51. (Pubitemid 34194843)
5. Segal BH, Freifeld AG, Baden LR, et al. Prevention and treatment of cancer-related infections. J Natl Compr Cancer Netw 2008;6:122-74. (Pubitemid 351340523)
6. Wingard JR. Antifungal chemoprophylaxis after blood and marrow transplantation. Clin Infect Dis 2002;34:1386-90. (Pubitemid 34507949)
7. Maertens J. Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies. Eur J Haematol 2007;78:275-82. (Pubitemid 46365078)
8. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328-40.
9. Schimpff SC. Empiric antibiotic therapy for granulocytopenic cancer patients. Am J Med 1986;80:13-20. (Pubitemid 16090510)
10. Cho SY, Choi HY. Opportunistic fungal infection among cancer patients: a ten-year autopsy study. Am J Clin Pathol 1979;72:617-21. (Pubitemid 10247863)
11. Lazarus HM, Creger RJ, Gerson SL. Infectious emergencies in oncology patients. Semin Oncol 1989;16:543-60. (Pubitemid 20022556)
12. Kibbler CC. Empirical antifungal therapy in febrile neutropenic patients: current status. Curr Top Med Mycol 1997;8:5-14.
13. Boelaert JR, Fenves AZ, Coburn JW. Deferoxamine therapy and mucormycosis in dialysis patients: report of an international registry. Am J Kidney Dis 1991;18:660-7.
14. Maertens J, Demuynck H, Verbeken EK, et al. Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis. Bone Marrow Transplant 1999;24:307-12. (Pubitemid 29377872)
15. Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 1992;10:316-22.
16. Camps IR. Risk factors for invasive fungal infections in haematopoietic stem cell transplantation. Int J Antimicrob Agents 2008;32(suppl 2):S119-23.
17. Martino R, Subira M, Rovira M, et al, for the alloPBSCT Infectious/Non-infectious Complications Subcommittees of the Grupo Espanol de Trasplante Hematopoyetico (GETH). Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol 2002;116:475-82. (Pubitemid 34155525)
18. Bow EJ, Loewen R, Cheang MS, Shore TB, Rubinger M, Schacter B. Cytotoxic therapy-induced D-xylose malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia in adults. J Clin Oncol 1997;15:2254-61. (Pubitemid 27251126)
19. Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000;181:309-16. (Pubitemid 30049062)
20. Bennett JE, Powers J, Walsh T, et al. Forum report: issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis 2003;36(suppl 3):S117-22.
21. de Pauw BE, Sable CA, Walsh TJ, et al. Impact of alternate definitions of fever resolution on the composite endpoint in clinical trials of empirical antifungal therapy for neutropenic patients with persistent fever: analysis of results from the caspofungin empirical therapy study. Transpl Infect Dis 2006;8:31-7.
22. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990;12:308-29.
23. The EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989;86(6 pt 1):668-72.
24. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982;72:101-11. (Pubitemid 12090793)
25. Prentice HG, Hann IM, Herbrecht R, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997;98:711-18. (Pubitemid 27386554)
26. Walsh TJ, Finberg RW, Arndt C, et al, for the National Institute of Allergy and Iinfectious Diseases Mycoses Study Group. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999;340:764-71. (Pubitemid 29114295)
27. Wingard JR, White MH, Anaissie E, et al, for the L Amph/ABLC Collaborative Study Group. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis 2000;31:1155-63.
28. Fleming RV, Kantarjian HM, Husni R, et al. Comparison of amphotericin B lipid complex (ABLC) vs ambisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk Lymphoma 2001;40:511-20. (Pubitemid 32303242)
29. Anderson RP, Clark DA. Amphotericin B toxicity reduced by administration in fat emulsion. Ann Pharmacother 1995;29:496-500.
30. Gallagher JC, MacDougall C, Ashley ES, Perfect JR. Recent advances in antifungal pharmacotherapy for invasive fungal infections. Expert Rev Anti Infect Ther 2004;2:253-68. (Pubitemid 38735769)
31. Frothingham R. Lipid formulations of amphotericin B for empirical treatment of fever and neutropenia. Clin Infect Dis 2002;35:896-8.
32. Dignani MC, Anaissie E. Human fusariosis. Clin Microbiol Infect 2004;10(suppl 1):67-75. (Pubitemid 38379952)
33. Viscoli C, Castagnola E, Van Lint MT, et al. Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial. Eur J Cancer 1996;32A:814-20.
34. Malik IA, Moid I, Aziz Z, Khan S, Suleman M. A randomized comparison of fluconazole with amphotericin B as empiric antifungal agents in cancer patients with prolonged fever and neutropenia. Am J Med 1998;105:478-83. (Pubitemid 29013332)
35. Silling G, Fegeler W, Roos N, Essink M, Buchner T. Early empiric antifungal therapy of infections in neutropenic patients comparing fluconazole with amphotericin B/flucytosine. Mycoses 1999;42(suppl 2):101-4. (Pubitemid 30253120)
36. Winston DJ, Hathorn JW, Schuster MG, Schiller GJ, Territo MC. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med 2000;108:282-9. (Pubitemid 30110456)
37. Boogaerts M, Winston DJ, Bow EJ, et al, for the Itraconazole Neutropenia Study Group. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy: a randomized, controlled trial. Ann Intern Med 2001;135:412-22.
38. Schuler U, Bammer S, Aulitzky WE, et al. Safety and efficacy of itraconazole compared to amphotericin B as empirical antifungal therapy for neutropenic fever in patients with haematological malignancy. Onkologie 2007;30:185-91. (Pubitemid 46482161)
39. Walsh TJ, Pappas P, Winston DJ, et al, for the National Institute of Allergy and Infectious Diseases Mycoses Study Group. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346:225-34. (Pubitemid 34438861)
40. Ullmann AJ, Cornely OA, Burchardt A, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006;50:658-66. (Pubitemid 43190980)
41. Fukuda M, Hirashima K, Kurane R, et al. Empiric therapy with fluconazole in granulocytopenic patients with carcinoma or leukemia [in Japanese]. Jpn J Antibiot 1994;47:1065-70. (Pubitemid 24275303)
42. Vandewoude K, Vogelaers D, Decruyenaere J, et al. Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units. Antimicrob Agents Chemother 1997;41:2714-18. (Pubitemid 27524745)
43. Johnson JR. Voriconazole versus liposomal amphotericin B for empirical antifungal therapy. N Engl J Med 2002;346:1745-7. (Pubitemid 34547491)
44. Herbrecht R, Denning DW, Patterson TF, et al, for the Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-15.
45. Nucci M, Marr KA. Emerging fungal diseases. Clin Infect Dis 2005;41:521-6. (Pubitemid 41099648)
46. Bruggemann RJ, Alffenaar JW, Blijlevens NM, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 2009;48:1441-58.
47. Powers JH, Dixon CA, Goldberger MJ. Voriconazole versus liposomal amphotericin B in patients with neutropenia and persistent fever. N Engl J Med 2002;346:289-90. (Pubitemid 34438872)
48. Apisarnthanarak A, Little JR, Tebas P. Voriconazole versus liposomal amphotericin B for empirical antifungal therapy. N Engl J Med 2002;346:1745-7. (Pubitemid 34547491)
49. Walsh TJ, Lee J, Dismukes WE. Decisions about voriconazole versus liposomal amphotericin B [letter]. N Engl J Med 2002;346:1499. (Pubitemid 34755723)
50. Przepiorka D, Buadi FK, McClune B. Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia. Pharmacotherapy 2008;28:58-63.
51. Shehab N, DePestel DD, Mackler ER, Collins CD, Welch K, Erba HP. Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia. Pharmacotherapy 2007;27:970-9. (Pubitemid 46986683)
52. Nagappan V, Deresinski S. Reviews of anti-infective agents: posaconazole - a broad-spectrum triazole antifungal agent. Clin Infect Dis 2007;45:1610-17. (Pubitemid 351411847)
53. Maertens J, Raad I, Petrikkos G, et al, for the Caspofungin Salvage Aspergillosis Study Group. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004;39:1563-71.
54. Mora-Duarte J, Betts R, Rotstein C, et al, for the Caspofungin Invasive Candidiasis Study Group. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2020-9. (Pubitemid 35461658)
55. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004;351:1391-402.
56. Yanada M, Kiyoi H, Murata M, et al. Micafungin, a novel antifungal agent, as empirical therapy in acute leukemia patients with febrile neutropenia. Intern Med 2006;45:259-64.
57. Toubai T, Tanaka J, Ota S, et al. Efficacy and safety of micafungin in febrile neutropenic patients treated for hematological malignancies. Intern Med 2007;46:3-9. (Pubitemid 46062246)
58. van Burik JA, Ratanatharathorn V, Stepan DE, for the National Institute of Allergy and Infectious Diseases Mycoses Study Group. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004;39:1407-16.